Evidence map›Paper›PMID 38739668›Full record

ArticlePloS one2024

The clinical significance of long non-coding RNAs MALAT1 and CASC2 in the diagnosis of HCV-related hepatocellular carcinoma.

Rehab M Golam, Mahmoud A F Khalil, Olfat G Shaker, Tarek I Ahmed, Mohamed K Abd Elguaad, Essam A Hassan, Mahmoud R M El-Ansary, Ahmed Ismail, Yasser I Kandil, Osama A Mohammed and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rehab M GolamDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Mahmoud A F KhalilDepartment of Microbiology and Immunology, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.
Olfat G ShakerDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Tarek I AhmedDepartment of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Mohamed K Abd ElguaadDepartment of Medical Physiology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Essam A HassanDepartment of Tropical Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Mahmoud R M El-AnsaryDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Misr University for Science and Technology (MUST), Giza, Egypt.
Ahmed IsmailBiochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
Yasser I KandilBiochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
Osama A MohammedDepartment of Pharmacology, College of Medicine, University of Bisha, Bisha, Saudi Arabia.
Ahmed S DoghishDepartment of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, Egypt.ORCID 0000-0002-0136-7096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlobally, hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death due to a lack of early predictive and/or diagnostic tools. Thus, research for a new biomarker is important. LncRNAs play a functional role in target gene regulation and their deregulation is associated with several pathological conditions including HCC.

objectiveThis study aimed to explore the diagnostic potential of two LncRNAs MALAT1 and CASC2 in HCC compared to the routinely used diagnostic biomarker. MATERIALS AND

methodsThe current study is a case-control study carried out at Fayoum University Hospital and conducted on 89 individuals. The study included three groups of 36 HCC patients on top of HCV(HCC/HCV), 33 HCV patients, and 20 healthy volunteers as a control group. All study subjects were subjected to radiological examinations. The determination of CBC was performed by the automated counter and liver function tests by the enzymatic method were performed. In addition, HCV RNA quantification and the expression level of two LncRNAs (MALAT1 and CASC2) were performed by qRT-PCR.

resultsThe results revealed a statistically significant difference between study groups regarding liver function tests with a higher mean in HCC/HCV group. Also, serum MALAT1 significantly up-regulated in HCV (11.2±2.8) and HCC/HCV (4.56±1.4) compared to the control group. Besides, serum CASC2 levels in the HCV group were significantly upregulated (14.9±3.6), while, downregulated in the HCC group (0.16± 0.03). Furthermore, The ROC analysis for diagnostic efficacy parameters indicated that CASC2 has higher accuracy (94.6%) and sensitivity (97.2%) for HCC diagnosis than AFP with an accuracy of (90.9%), sensitivity (69.4%), and MALAT1 showed an accuracy of (56.9%), sensitivity (72.2%).

conclusionOur study results indicated that CASC2 is a promising biomarker and is considered better and could help in HCC diagnosis on top of HCV than MALAT1 and the routine biomarker AFP.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsRNA, Long NoncodingTumor Suppressor ProteinsAdultAgedCase-Control StudiesClinical RelevanceFemaleGene Expression Regulation, NeoplasticHepacivirusHepatitis CHumansMaleMiddle AgedBiomarkers, Tumorlong non-coding RNA CASC2, humanMALAT1 long non-coding RNA, humanRNA, Long NoncodingTumor Suppressor Proteins

Identifiers

PMID38739668
PMCPMC11090319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.